Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses

Journal of Veterinary Pharmacology and Therapeutics

Volumn 35, Issue 1, 2012, Pages 97-104

  Takeuchi, Y ^a   Fujino, Y ^a   Fukushima, K ^a   Watanabe, M ^b   Nakagawa, T ^a   Ohno, K ^a   Sasaki, N ^a   Sugano, S ^b   Tsujimoto, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CYCLOSPORIN; IMATINIB; MASITINIB; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR; VATALANIB;

ANIMAL CELL; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DOG; DRUG EFFECT; GENE EXPRESSION; IC 50; MASTOCYTOMA; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; MAST CELLS; MASTOCYTOMA; ORGANIC ANION TRANSPORTERS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RNA, MESSENGER;

EID: 84855508658     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2011.01296.x     Document Type: Article

References (37)

1. Bennasroune, A., Gardin, A., Aunis, D., Cremel, G. & Hubert, P. (2004) Tyrosine kinase receptors as attractive targets of cancer therapy. Critical Reviews in Oncology/Hematology, 50, 23-38.
2. Blott, E.J., Higgins, C.F. & Linton, K.J. (1999) Cysteine-scanning mutagenesis provides no evidence for the extracellular accessibility of the nucleotide-binding domains of the multidrug resistance transporter P-glycoprotein. EMBO Journal, 18, 6800-6808.
3. Dobson, J.M. & Scase, T.J. (2007) Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. Journal of Small Animal Practice, 48, 424-431.
4. Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Casteran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., Voisset, E., Arock, M., Auclair, C., Leventhal, P.S., Mansfield, C.D., Moussy, A. & Hermine, O. (2009) Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE, 4, e7258.
5. Gilfillan, A.M. & Rivera, J. (2009) The tyrosine kinase network regulating mast cell activation. Immunological Reviews, 228, 149-169.
6. Gleixner, K.V., Rebuzzi, L., Mayerhofer, M., Gruze, A., Hadzijusufovic, E., Sonneck, K., Vales, A., Kneidinger, M., Samorapoompichit, P., Thaiwong, T., Pickl, W.F., Yuzbasiyan-Gurkan, V., Sillaber, C., Willmann, M. & Valent, P. (2007) Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Experimental Hematology, 35, 1510-1521.
7. Hahn, K.A., Ogilvie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P.S., Kinet, J.P., Palmerini, F., Dubreuil, P., Moussy, A. & Hermine, O. (2008) Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine, 22, 1301-1309.
8. Hegedus, C., Ozvegy-Laczka, C., Apati, A., Magocsi, M., Nemet, K., Orfi, L., Keri, G., Katona, M., Takats, Z., Varadi, A., Szakacs, G. & Sarkadi, B. (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. British Journal of Pharmacology, 158, 1153-1164.
9. Hess-Stumpp, H., Haberey, M. & Thierauch, K.H. (2005) PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem, 6, 550-557.
10. Honjo, Y., Hrycyna, C.A., Yan, Q.W., Medina-Perez, W.Y., Robey, R.W., van de Laar, A., Litman, T., Dean, M. & Bates, S.E. (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Research, 61, 6635-6639.
11. Hu-Lowe, D.D., Zou, H.Y., Grazzini, M.L., Hallin, M.E., Wickman, G.R., Amundson, K., Chen, J.H., Rewolinski, D.A., Yamazaki, S., Wu, E.Y., McTigue, M.A., Murray, B.W., Kania, R.S., O'Connor, P., Shalinsky, D.R. & Bender, S.L. (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clinical Cancer Research, 14, 7272-7283.
12. Ishizuka, M., Nagai, S., Sakamoto, K.Q. & Fujita, S. (2007) Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. Xenobiotica, 37, 503-513.
13. Isotani, M., Ishida, N., Tominaga, M., Tamura, K., Yagihara, H., Ochi, S., Kato, R., Kobayashi, T., Fujita, M., Fujino, Y., Setoguchi, A., Ono, K., Washizu, T. & Bonkobara, M. (2008) Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine, 22, 985-988.
14. Jost, L.M., Gschwind, H.P., Jalava, T., Wang, Y., Guenther, C., Souppart, C., Rottmann, A., Denner, K., Waldmeier, F., Gross, G., Masson, E. & Laurent, D. (2006) Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metabolism and Disposition, 34, 1817-1828.
15. Kitazaki, T., Oka, M., Nakamura, Y., Tsurutani, J., Doi, S., Yasunaga, M., Takemura, M., Yabuuchi, H., Soda, H. & Kohno, S. (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer, 49, 337-343.
16. Letard, S., Yang, Y., Hanssens, K., Palmerini, F., Leventhal, P.S., Guery, S., Moussy, A., Kinet, J.P., Hermine, O. & Dubreuil, P. (2008) Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Molecular Cancer Research, 6, 1137-1145.
17. Liao, A.T., Chien, M.B., Shenoy, N., Mendel, D.B., McMahon, G., Cherrington, J.M. & London, C.A. (2002) Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood, 100, 585-593.
18. London, C.A. (2009) Tyrosine kinase inhibitors in veterinary medicine. Topics in Companion Animal Medicine, 24, 106-112.
19. London, C.A., Galli, S.J., Yuuki, T., Hu, Z.Q., Helfand, S.C. & Geissler, E.N. (1999) Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Experimental Hematology, 27, 689-697.
20. London, C.A., Malpas, P.B., Wood-Follis, S.L., Boucher, J.F., Rusk, A.W., Rosenberg, M.P., Henry, C.J., Mitchener, K.L., Klein, M.K., Hintermeister, J.G., Bergman, P.J., Couto, G.C., Mauldin, G.N. & Michels, G.M. (2009) Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research, 15, 3856-3865.
21. Ma, Y., Longley, B.J., Wang, X., Blount, J.L., Langley, K. & Caughey, G.H. (1999) Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. The Journal of Investigative Dermatology, 112, 165-170.
22. Mahon, F.X., Belloc, F., Lagarde, V., Chollet, C., Moreau-Gaudry, F., Reiffers, J., Goldman, J.M. & Melo, J.V. (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood, 101, 2368-2373.
23. Manley, P.W., Cowan-Jacob, S.W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, T. & Zimmermann, J. (2002) Imatinib: a selective tyrosine kinase inhibitor. European Journal of Cancer, 38 (Suppl. 5), S19-S27.
24. Miyoshi, N., Tojo, E., Oishi, A., Fujiki, M., Misumi, K., Sakamoto, H., Kameyama, K., Shimizu, T. & Yasuda, N. (2002) Immunohistochemical detection of P-glycoprotein (PGP) and multidrug resistance-associated protein (MRP) in canine cutaneous mast cell tumors. Journal of Veterinary Medical Science, 64, 531-533.
25. Nakaichi, M., Takeshita, Y., Okuda, M., Nakamoto, Y., Itamoto, K., Une, S., Sasaki, N., Kadosawa, T., Takahashi, T. & Taura, Y. (2007) Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines. Journal of Veterinary Medical Science, 69, 111-115.
26. Ohmori, K., Kawarai, S., Yasuda, N., Tanaka, A., Matsuda, H., Nishimura, R., Sasaki, N., Tsujimoto, H. & Masuda, K. (2008) Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells. Veterinary Immunology and Immunopathology, 126, 43-53.
27. Peter, B., Hadzijusufovic, E., Blatt, K., Gleixner, K.V., Pickl, W.F., Thaiwong, T., Yuzbasiyan-Gurkan, V., Willmann, M. & Valent, P. (2010) KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Experimental Hematology, 38, 782-791.
28. Pithavala, Y.K., Tortorici, M., Toh, M., Garrett, M., Hee, B., Kuruganti, U., Ni, G. & Klamerus, K.J. (2010) Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemotherapy and Pharmacology, 65, 563-570.
29. Rebuzzi, L., Willmann, M., Sonneck, K., Gleixner, K.V., Florian, S., Kondo, R., Mayerhofer, M., Vales, A., Gruze, A., Pickl, W.F., Thalhammer, J.G. & Valent, P. (2007) Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Veterinary Immunology and Immunopathology, 115, 320-333.
30. Roskoski, R. Jr (2005a) Signaling by Kit protein-tyrosine kinase - the stem cell factor receptor. Biochemical and Biophysical Research Communications, 337, 1-13.
31. Roskoski, R. Jr (2005b) Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochemical and Biophysical Research Communications, 338, 1307-1315.
32. Schrickx, J.A. & Fink-Gremmels, J. (2008) Implications of ABC transporters on the disposition of typical veterinary medicinal products. European Journal of Pharmacology, 585, 510-519.
33. Takahashi, T., Kitani, S., Nagase, M., Mochizuki, M., Nishimura, R., Morita, Y. & Sasaki, N. (2001) IgG-mediated histamine release from canine mastocytoma-derived cells. International Archives of Allergy and Immunology, 125, 228-235.
34. Takeuchi, Y., Fujino, Y., Watanabe, M., Nakagawa, T., Ohno, K., Sasaki, N., Sugano, S. & Tsujimoto, H. (2010) Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines. Veterinary Immunology and Immunopathology, 137, 208-216.
35. Tang, F., Ouyang, H., Yang, J.Z. & Borchardt, R.T. (2004) Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers. Journal of Pharmaceutical Sciences, 93, 1185-1194.
36. Welle, M.M., Bley, C.R., Howard, J. & Rufenacht, S. (2008) Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Veterinary Dermatology, 19, 321-339.
37. Zhou, S.F. (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica, 38, 802-832.